Literature DB >> 16996870

Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.

Małgorzata Pyda1, Katarzyna Korybalska, Krzysztof Ksiazek, Stefan Grajek, Magdalena Lanocha, Maciej Lesiak, Justyna Wiśniewska-Elnur, Anna Olasińska, Andrzej Breborowicz, Andrzej Cieśliński, Janusz Witowski.   

Abstract

It has been demonstrated that high blood vascular endothelial growth factor (VEGF) levels in patients with myocardial infarction decrease rapidly after reperfusion, possibly in response to heparin administration. We measured serum VEGF concentration before and after heparin infusion in 105 patients with ST-elevation acute myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). Serum VEGF concentration in patients with STEMI was significantly higher than in healthy controls. After PCI, the concentration of VEGF decreased by approximately 70%, with the greatest decrease seen in patients with the highest initial VEGF levels. To determine whether heparin could decrease VEGF concentration by sequestering VEGF in the endothelium, a fixed dose of recombinant VEGF was incubated for 40 minutes with EA.hy926 endothelial cells in vitro. Recovery of VEGF from medium after culture was decreased by up to 15% with increasing doses of heparin. Concentration of VEGF did not change in the absence of heparin and/or endothelial cells. In conclusion, these results suggest that a rapid decrease in blood VEGF after PCI may be related to the administration of heparin, which binds simultaneously to VEGF and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996870     DOI: 10.1016/j.amjcard.2006.04.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction.

Authors:  Katarzyna Korybalska; Małgorzata Pyda; Stefan Grajek; Magdalena Lanocha; Andrzej Breborowicz; Janusz Witowski
Journal:  Clin Res Cardiol       Date:  2010-02-07       Impact factor: 5.460

Review 2.  The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.

Authors:  Eleni Papakonstantinou; George Karakiulakis
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.